NIH R01 · 2025
Leptomeningeal Disease (LMD) occurs in 5% of advanced stage breast cancer (BC) patients, with an overall survival measured in weeks. While there is an unmet need for better treatment strategy, the knowledge about the biology of LMD in general is scarce. Novel approaches with a better understanding of this disease will benefit in developing a cure. Here we propose using polarized conventional Type I dendritic cell (cDC1) therapy (as a therapeutic and a vaccine) where cDC1s are primed with HER2 and HER3 to treat HER2+ BC and triple negative BC (TNBC) associated LMD. In murine models & clinical trials of systemic breast tumors we have found that class II HER2/HER3 peptide-pulsed Type I…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.